Biotech Values

[semi_infinite]

NVS Entresto - It is clearly better for the patients further along the NYHA heart failure scale relative to entrenched generic ACE inhibitors. Many cardiologist will stick with enalapril because HF is a slow progression disease so why switch at an incremental cost of $4K/yr. It is a quality of life question for HF patients, ie how long do they wait? how low of an ejection fraction can they live with? The management of HF patients is still very archaic, eg some docs are still regularly using amiodarone, digoxin etc.. NVS underestimated the stickiness of inferior drugs and time scale of adoption.

MYOK will face the same issues even if their molecules are proven to be useful. I have doubts on their first molecule.